Strategic Partnerships Aimmune is a Nestlé Health Science company with a history of collaboration, including the Nestlé partnership around Palforzia. This suggests potential alignment opportunities with large consumer-health players and opportunity to leverage existing distribution, regulatory, and medical affairs capabilities.

Global footprint With offices in the United States and Europe (Brisbane, CA; Durham, NC; London; Dublin; Munich) and a focus on food allergy therapies, there are multiple regional markets to target for expansion, regulatory support, and local clinical access programs.

FDA approved core Having an FDA-approved peanut allergy therapy indicates validated clinical and commercial proof-of-concept, enabling upsell or expansion conversations around additional allergen desensitization programs and companion diagnostics or monitoring tools.

Financial runway Funding of substantial magnitude (approximately $540M) alongside reported revenue in the tens of millions provides a runway for co-development deals, milestone-driven partnerships, and joint ventures with larger biopharma seeking late-stage allergy assets.

Clinical momentum Ongoing development of CODIT platform and multiple investigational therapies signals a opportunities pipeline for corporate collaborations, CRO/CDMO services, and shared risk-reward programs with players aiming to broaden the food allergy portfolio.